Evidence map›Paper›PMID 29789926›Full record

ArticleJournal of cancer research and clinical oncology2018

Patterns of platinum drug use in an acute care setting: a retrospective study.

Evangeline Armstrong-Gordon, Danijela Gnjidic, Andrew J McLachlan, Bayan Hosseini, Andrew Grant, Philip J Beale, Nial J Wheate

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 30 citations in OpenAlex.

  1. Current clinical applications and future developments of platinum-based anticancer drugs.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026
    Review
  2. Article
  3. Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent.Journal of the American Chemical Society · 2019
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Evangeline Armstrong-GordonSydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia.
Danijela GnjidicSydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia. danijela.gnjidic@sydney.edu.au.ORCID http://orcid.org/0000-0002-9404-3401
Andrew J McLachlanSydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia.ORCID http://orcid.org/0000-0003-4674-0242
Bayan HosseiniOncology Pharmacy Department, Concord Repatriation General Hospital, Sydney Local Health District, Sydney, NSW, 2139, Australia.
Andrew GrantOncology Pharmacy Department, Concord Repatriation General Hospital, Sydney Local Health District, Sydney, NSW, 2139, Australia.
Philip J BealeConcord Cancer Centre, Concord Repatriation General Hospital and Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.
Nial J WheateSydney Pharmacy School, The University of Sydney, Sydney, NSW, 2006, Australia. nial.wheate@sydney.edu.au.ORCID http://orcid.org/0000-0002-0505-1363
The University of Sydney · AUConcord Repatriation General Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePlatinum drugs have been in use in cancer treatment for more than 40 years, but little is known about the pattern of their use. The aim of this study was to examine the patterns of platinum drug use, with a secondary aim to describe the occurrence of dose reductions.

methodsA retrospective analysis was conducted of oncology pharmacy dispensing records from a single hospital in Australia. Data related to drug choice, regimen and dose reductions were included in this study if the patient had received their last round of chemotherapy between November 2014 and July 2015.

resultsOf the 156 patients included in the study, 46% were dispensed a platinum drug during their treatment. The most commonly dispensed drugs were cisplatin (40%), carboplatin (40%) and oxaliplatin (15%), while some patients (5%) received more than one platinum drug. Dose reductions were more common in patients who were treated with a platinum drug (73%) compared with patients treated with non-platinum drugs (55%). The most common reason for a dose reduction was cytopenia.

conclusionsThe findings suggest that platinum drugs remain one of the most commonly dispensed drugs to treat cancer patients and most patients receive a dose reduction during treatment.

Indexed as

AgedAntineoplastic AgentsAustraliaDrug TherapyFemaleHumansMaleMiddle AgedNeoplasmsOrganoplatinum CompoundsPharmacy Service, HospitalRetrospective StudiesAntineoplastic AgentsOrganoplatinum CompoundsCancerChemotherapyDose reductionsPlatinum drugsPrescribing

Identifiers

PMID29789926
PMCPMC11813513
OpenAlexW2803475230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.